NEW YORK (GenomeWeb News) – Theradiag said today that it has received the CE Mark for two new biotherapy monitoring kits: tocilizumab and rituximab. Tocilizumab is an immunosuppressive drug used to treat rheumatoid arthritis and juvenile idiopathic arthritis, while rituximab is prescribed for treatment of leukemia and lymphoma. The Theradiag kits are sold under the Lisa Tracker brand name.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.